Authors
Latest:
FDA Approval Insights: Afami-Cel for Pretreated, Unresectable or Metastatic Synovial SarcomaDr Warner discusses the FDA approval of afami-cel for patients with advanced synovial sarcoma and key findings from the pivotal SPEARHEAD-1 trial.
Latest:
Dr. Rosenthal on FDA Approval of Ibrutinib in Marginal Zone LymphomaAllison C. Rosenthal, DO, hematology consultant, Mayo Clinic, discusses the FDA approval of of ibrutinib (Imbruvica) as a treatment for patients with marginal zone lymphoma (MZL).
Latest:
Oncology Payment Models Fall Short of Desired GoalsThere is a year and a half remaining in the life of the Oncology Care Model, and although the Centers for Medicare & Medicaid Services has leapt forward with a vision for the next-generation model of care Oncology Care First, many stakeholders feel that the Oncology Care Model is more than enough to think about right now.
Latest:
Managing Obesity in Survivors of Gynecologic CancerWith nearly 40% of the adult population in the Unites States classified as obese, gynecologic oncologists must be ready to address the specific needs and considerations for this population, including for patients who have entered survivorship.
Latest:
Immunotherapy: Personalized Treatment for Advanced Prostate CancerIn April 2010, the FDA approved sipuleucel-T for patients with castration-resistant and metastatic prostate cancer, providing a new treatment that would help the body fight its own cancer.
Latest:
Dr. Kurian on Association of Ovarian Cancer Risk With Mutations Detected by Multiple-Gene Germline SequencingAllison W. Kurian, MD, MSc, associate professor of Medicine and of Health Research and Policy, Stanford University School of Medicine, discusses an ongoing trial exploring the association of ovarian cancer risk with mutations detected by multiple-gene germline sequencing in 95,561 women.
Latest:
Internal Investigations May be Open to Court and Government Agency ScrutinyGiven a handful of recent cases, and a recent update to the CMS Voluntary Self-Referral Disclosure Protocol, it appears that the federal government may be using the existence of these audits as a means for demonstrating that the provider "knew or should have known" that fraud occurred.
Latest:
Survivorship and Chronic Pain Management for Cancer PainThe rise in survivorship has increased chronic pain in the cancer pain population, the treatment of which has many fundamental differences when compared to acute and terminal cancer pain.
Latest:
Dr. Ocean on the Toxicities With SM-88 in Metastatic Pancreatic CancerAllyson J. Ocean, MD, discusses her experiences with SM-88 in patients with metastatic pancreatic cancer.
Latest:
Dr. Ocean on Determining Optimal Frontline Treatments for Metastatic Pancreatic CancerAllyson Ocean, MD, discusses determining the optimal frontline treatment of patients with metastatic pancreatic cancer.
Latest:
Changing the Face of Lung Cancer in Kentucky: New Program May Serve as National ModelThe efforts of the Kentucky LEADS Collaborative offer a unique opportunity to change the face of lung cancer in Kentucky by harnessing new lung cancer care and control strategies.
Latest:
Dr. Khorana on Rates of Young-Onset Pancreatobiliary AdenocarcinomaAlok Khorana, MD, discusses increasing rates of young-onset pancreatobiliary adenocarcinoma.
Latest:
Dr. Altman on Neoadjuvant Chemotherapy in High-Grade Serous CarcinomaAlon Altman, MD, associate professor, Department of Obstertrics, Gynecology and Reproductive Sciences, University of Manitoba, discusses neoadjuvant chemotherapy for patients with high-grade serous carcinoma.
Latest:
Hypofractionated and Stereotactic Body Radiotherapy in Prostate CancerDespite limited data comparing stereotactic body radiation therapy to standard or hypofractionated radiotherapy with regards to long-term clinical outcomes and toxicity profiles, the data are promising and appropriately selected patients can be offered such an approach off-protocol.
Latest:
Dr. Schmaier on Managing Cancer-Associated ThrombosisAlvin H. Schmaier, MD, professor in the Department of Medicine and the Department of Pathology at Case Western Reserve University School of Medicine, discusses the management of patients with cancer-associated thrombosis.
Latest:
Dr. Lalani on a Study of Neutrophil-Lymphocyte Ratio in RCCAly-Khan Lalani, MD, genitourinary oncology fellow, Dana-Farber Cancer Institute, discusses the results of a study investigating neutrophil-lymphocyte ratio (NLR) in patients with renal cell carcinoma (RCC).
Latest:
Growing Pains: OCM Results Need Close LookDarcie Hurteau, MBA, and Alyssa Dahl, PhD, MPH, discuss the growing pains of the Oncology Care Model, a complicated payment program that is still establishing administrative processes.
Latest:
Oncology Care Model Practices Await CMS Report CardsAlyssa Dahl, MPH, CPH, discusses what to watch for when the CMS releases performance results for the Oncology Care Model.
Latest:
Patient-Contributed Tumor Genetics Data: A Pathway to Better Drug Development?Developing companion diagnostics has several associated challenges related to cost, access to samples, and clinical trial recruitment.
Latest:
Dr. Chauhan on Future Directions With Lutathera in GEP-NETsAman Chauhan, MD, discusses future directions with Lutathera in gastroenteropancreatic neuroendocrine tumors.
Latest:
Organizing a Fellows' Career DayEverybody is aware that career choices in oncology abound these days. But when you ask fellows what job they are interested in once they complete their fellowship, many just don't know-even in their third year.
Latest:
Dr Fader on Letrozole With or Without Paclitaxel and Carboplatin in Ovarian Serous CarcinomaAmanda Nickles Fader, MD, discusses the randomized, phase 3 NRG-GY019 trial evaluating letrozole with or without paclitaxel and carboplatin in patients with stage II to IV primary low-grade serous carcinoma of the ovary or peritoneum.
Latest:
Navigating the Job Search for Surgical Oncology FellowsAs the end of training approaches, the job hunt begins. Below are some tips to follow to make the job-hunting process easier.
Latest:
A Phase III Randomized Trial of MRI-Mapped, Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS TrialTreating MRI-identified prostate lesions to definitive doses using an SIHB is possible without significantly increased dose or acute toxicity to critical structures
Latest:
Decision Support Systems in Oncology: Are we there yet?The push for clinical decision support technology in medicine is a logical consequence of our experiences as consumers and the need for intelligent support at the bedside.
Latest:
Dr. Karam on the Role of Debulking Surgery in Recurrent Ovarian CancerAmer Karam, MD, discusses determining whether to use debulking surgery after recurrence in ovarian cancer.
Latest:
How Do I Keep Up With the Literature?As an oncology fellow pursuing an academic career, one of the major challenges Amer M. Zeidan faces is balancing clinical duties and research activities.
Latest:
Final Thoughts on EHA 2024 Data for Lower-Risk MDSKey opinion leaders summarize their main insights and key takeaways from the EHA 2024 conference regarding advances in lower-risk myelodysplastic syndrome treatment.
Latest:
How to Plan for Your Conference TripI still remember my first time attending the annual American Society of Hematology meeting in 2008.
